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Thispaper describes the effects of re-engineering, or businessprocess
engineering, on the pharmaeutical industry. It then extrapolates the
re-engineering fever to the field of analytical chemistry and shows
that the use of automation will concomitantly increase over the next
several years. This will require a fresh look at projects and
situations that can be automated, as well as those thoughtpreviously
non-automatable. The ability of laboratory personnel to ’think out
of the box’ will dictate their rise or fall as successful analysts.
Business process re-engineering
At the International Symposium on Laboratory Auto-
mation and Robotics (ISLAR) over the past several years,
many presentations during the plenary and management
sessions have dealt with the concept and reality of’doing
much more with much less.., faster!’ The various forces
at work shaping the future of the pharmaceutical industry
have affected everyone working in research and develop-
ment. The containment of research and development
costs, coupled with the need to improve profitability
without raising prices, have forced drug manufacturers to
reorganize, merge, acquire other companies (both large
and small), downsize, redirect research efforts, and
improve productivity. Intense analyses and benchmarking
of companies against one another have made consultants
rich and have resulted in the largest wave of change to
sweep the pharmaceutical industry since the advent of
Federal Drug Laws. Activities which were ’nice to have’
are now a thing of the past. Research areas which do not
directly result in innovative new products that satisfy
medical needs have, or are being, abandoned. Research
and development are now driven by the market and the
bottom line of the corporation. In today’s aggressive
competitive situation, companies which do not adopt this
strategy will soon be out of the running.
Any new change brings with it a new language. Business
analysts have, for several years, preached about the
concept of ’re-engineering’ or, more precisely, ’business
process re-engineering’. The concept of business process
re-engineering, to quote directly from Hammer and
Champy [1], is as follows: ’Business process re-engineering
means starting over, starting from scratch. It means
putting aside much of the received wisdom of two
hundred years of industrial management. It means
forgetting how work was done in the age of the mass
market and deciding how it can best be done now’.
American business can no longer be content with
manufacturing a product that the customer will be
’content’ with, or supply a service which an end user will
simply’accept’. The American public now demands the
best quality and a product designed and manufactured
to their needs and specifications. In order to meet the
extreme demands placed upon them, American companies
have begun to critically examine the very processes by
which they conduct business. The word ’process’ is key;
many corporations as of now are set up according to
function and not process. This implies that each segment of
the business performs a certain task and then passes the
work on to the next function. This is very much akin to
the concept of assembly-line production made famous by
the automobile pioneer Henry Ford in the early years of
the 20th century. In the functionality mode, each discrete
function performs a given task without regard for what
preceded their interaction or what is to follow. This tends
to result in products and services which are no more than
the sum of their parts; however, the competition has come
to deliver products and services which are much more
than the sum of their individual functions. It is the latter
scenario that forms the basis for business process re-
engineering, which considers the process ofmanufacturing
goods or performing a service. In the process mode, a
team of individuals who are all thoroughly familiar with
the products or service at hand, perform the various tasks,
usually in a more efficient manner than the individual
functions. How can a smaller team ofindividuals turn out
a better product, faster and more efficiently? The answer
is found in the basic question asked during the re-
engineering process: ’Do not ask how we can do what we
do better, rather ask why we do what we do at all’.
Although this statement casts doubts on the way business
is performed now, it is nonetheless true. The concept of
functionalization entails having a larger workforce than
the process-oriented approach. This is traditionally due
to the need for ’doers’ and ’checkers’ in the functional
world, which ultimately results in hierarchical structures.
In a process-oriented structure, teams of individuals are
empowered by management to make decisions and move
a project from injection to completion. These teams of
individuals are given the maximum freedom and flexibility
within the corporate structure to cause changes in the
way the corporation conducts business to occur. Indeed,
the formal definition of business process re-engineering
summarizes its important concepts:
Business Process Re-engineering: A set ofprocedures for effecting
radical change in the way a corporation conducts some or all of
its business practices: the fundamental rethinking and radical
redesign of business processes to achieve dramatic improve-
ments in critical, contemporary measures of performance, such as
cost, quality, service and speed.
Re-engineering applied to the pharmaceutical
industry
The entire concept of business process re-engineering is
leaving its mark on the pharmaceutical industry, especially
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in the research and development area. The demand of
the American public on the pharmaceutical industry to
control costs has forced companies to react in a multitude
of ways. They have merged, acquired other companies,
reorganized and downsized. Last year at ISLAR, Dr
Philip Lane of R. W. Johnson PRI summarized these
trends in a presentation entitled ’The reality of the 90s
and beyond--more with less [2]. In his talk, Dr Lane
summarized the factors shaping the pharmaceutical
industry. These realities include stricter compliance (FDA
pre-approval inspections, Barr decision, implementation
of ICH guidelines), company mergers and acquisitions,
the diversity of the workforce and the necessity of having
work and family programmes. For pharmaceutical
companies to not only survive but prosper as well, he
stated that the ways in which we conduct business must
change. This implies a fresh look at old principles with
the intention of implementing drastic change.
Since all of the new realities discussed by Dr Lane will
impact the bottom line of the corporation, an obvious
answer is to either reduce costs and/or improve sales. With
the advent of cost restraint, a company’s answer to an
increased cost of business is no longer raising the prices
on the products it markets. It must therefore reduce its
cost of doing business, as well as bring new products to
market faster and more efficiently. A shorter time in the
R&D pipeline means less overall costs which need to be
recaptured in profits. Therefore, in theory, products
discovered and developed according to a streamlined
R&D strategy should be able to be more competitively
priced. Indeed, many large research-based pharmaceutical
companies are using such techniques as automated high
throughput screening assays and combinatorial chemistry
to search for ’hits’, which may result in a candidate
molecule worthy of development. These same corpor-
ations are aggressively seeking to improve their track
records with respect to bringing new molecules to market
faster, while at the same time, not compromising quality
and regulatory compliance. ’Breaking down the wall’
between research and development is becoming fairly
common in the pharmaceutical industry.
Automation and re-engineering analytical
chemistry
It is interesting that Hammer and Champy’s text devotes
a full chapter to the concept of information technology
(IT) as a necessary tool for re-engineering. They stress
that many of the re-engineering tasks performed today
could not have even been imagined twenty years ago. The
power of computing and electronic communication has
provided the opportunity to move information instan-
taneously and without error. This has made the working
world considerably smaller and has allowed larger
amounts of data and records to be handled by fewer
people.
The use of laboratory automation is obviously a part of
the concept of re-engineering analytical chemistry. Being
hybrids of computers, laboratory robots are a part of the
electronic revolution that has swept the industry. Originally
introduced into analytical laboratories involved in
supporting drug development, robotics techniques are
now routinely used in drug discovery as well. In the
robotics laboratory in the analytical research and develop-
ment at Hoffmann-La Roche, the way the business is
conducted is being re-engineered. In fact, the creation of
the department less than a year ago was a re-engineering
step in itself. Since the inception of analytical R&D, the
department has constantly strived to look for alternative
means ofaccomplishing its mission while at the same time
satisfying the needs of customers and remaining in
regulatory compliance.
Last year at ISLAR, the department presented its
management philosophy of a centralized/decentralized
approach to robotics in which a core group of individuals
is charged with the day-to-day operation of the robotics
laboratory and its associated equipment [3]. This includes
maintenance, troubleshooting, system validation and
method development. This core group of robotic specialists
then supports the other project-based groups who supply
the chemistry and the projects which are transferred to
the robots and workstations. The advantages ofthis hybrid
approach are:
(1) There is uniformity in equipment and validation.
(2) There is a mix of expertise in robotics and the
chemistry of the compound.
(3) People working on the project benefit from the sharing
of ideas and experience.
(4) People working on the automation project can possess
ownership without actually having to be a supervisor.
Automation is now being applied to projects in Phases 2
and 3 of clinical trials, as these are the projects which
result in the greatest number of samples. The philosophy
which was highlighted at last year’s ISLAR continues to
be in effect. Some ofthe newest robotic tasks have included
the automation of cleaning validation methodology,
which is a rather simple but nonetheless mundane task.
It is perfectly suited to the Zymark Benchmate. Additional
projects now currently underway include automation of
animal feed analysis for support ofGLP toxicology studies,
various biotechnology tests such as bioassay and veri-
fication of the exchange of methods with other develop-
ment centers having the same or similar equipment.
Conclusions
The use of robotics will play a large part in the
re-engineering trends underway in the pharmaceutical
industry discovery and development laboratories. The
R&D department at Hoffmann-La Roche is a repre-
sentative cross-section of the industry and its staff are
convinced that laboratory automation will truly be one
of the concepts that make the ’realities of the 1990s’ bear
fruit for pharmaceutical companies.
References
1. HAMMER, M. and CHAMPY, J., Reengineering the Corporation (1993).
2. LANE, P. A., In Proceedings of the 1994 ISLAR Meeting (Zymark,
Hopkinton, MA, 1994).
3. SCYPINSKI, S., NELSON, L. and SADLOWSIL T., In Proceedings of the 1994
ISLAR Meeting (Zymark, Hopkinton, MA, 1994).
148